Litigation Details for Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)
✉ Email this page to a colleague
Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-05-10 |
| Court | District Court, D. Minnesota | Date Terminated | 2023-10-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Katherine M Menendez |
| Jury Demand | None | Referred To | John F. Docherty |
| Patents | 7,491,725; 8,680,103 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Nanocopoeia, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-04-10 | 124 | Amended Order on Motion | title of the patents at issue are United States Patent No. 7,491,725 and United States Patent No. 8,680,…has two patents that claim the crystalline form of dasatinib: the ‘725 patent and ‘103 patent. 1 Defendant…current drug patent. It can do so by certifying that the listed drug is not patented, the patent has expired…alleges infringement of United States Patent No. 8,242,270, but that patent is not at issue in this motion. … compromises. The Act authorized patent term extensions for patent holders who lost time waiting for | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
